Study on HIF-PHI combined with iron supplement in treatment of renal anemia in rats.

ABSTRACT:

Background

Roxadustat is a novel hypoxia- inducible factor-prolyl hydroxylase inhibitor(HIF-PHI) used to treat anemia in chronic kidney disease (CKD) patients. It has been reported that roxadustat can slow down kidney damage and delay the development of kidney fibrosis. Anemia and iron deficiency are often associated with the vast majority CKD patients, and insufficient available iron or total iron storage is often the most common cause of anemia and ESAs resistance in CKD patients. The role of iron availability in the pathogenesis of anemia in chronic kidney disease has received increasing attention.

Objectives

To explore whether combined roxadustat and polysaccharide-iron complex (PIC) is more successful than standalone roxadustat, the appropriate iron supplement dosage an

SUBMITTER: Gao Z 

PROVIDER: S-EPMC11887227 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature